Glaucoma warning
Use caution if you have glaucoma or increased eye pressure.
Leaflet EVERIO 25mcg / 125mcg / dose pressurised inhalation suspension
- Product code:
- W68287001
- Quantity:
- 1
- Indicated for:
- asthma; chronic obstructive pulmonary disease
- Route of administration:
- inhalation
- Substance:
- salmeterol + fluticasone (beta-2 adrenergic agonist + glucocorticoid)
- ATC
- R03AK06 — Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Precautions:
Hyperglycemia
This medicine may increase blood sugar.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Salmeterol+fluticasone is a combination medication used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta-2 adrenergic agonist that relaxes airway muscles and improves airflow. Fluticasone is an inhaled corticosteroid that reduces inflammation and prevents exacerbations.
This combination is administered via inhalation, usually twice daily, and is indicated for patients requiring both bronchodilation and anti-inflammatory control. It is effective in reducing symptoms, preventing asthma attacks, and improving quality of life.
Common side effects include throat irritation, hoarseness, oral fungal infections (candidiasis), and tremors. In rare cases, severe adverse reactions such as paradoxical bronchospasm or adrenal suppression may occur. Patients are advised to rinse their mouth after use to reduce the risk of candidiasis.
Salmeterol+fluticasone is a valuable therapeutic option for patients with chronic respiratory conditions, providing effective symptom control and prevention of exacerbations.
This combination is administered via inhalation, usually twice daily, and is indicated for patients requiring both bronchodilation and anti-inflammatory control. It is effective in reducing symptoms, preventing asthma attacks, and improving quality of life.
Common side effects include throat irritation, hoarseness, oral fungal infections (candidiasis), and tremors. In rare cases, severe adverse reactions such as paradoxical bronchospasm or adrenal suppression may occur. Patients are advised to rinse their mouth after use to reduce the risk of candidiasis.
Salmeterol+fluticasone is a valuable therapeutic option for patients with chronic respiratory conditions, providing effective symptom control and prevention of exacerbations.
General data about EVERIO 25mcg / 125mcg / dose
- Substance:
- salmeterol + fluticasone
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W68287001
- Concentration:
- 25mcg / 125mcg / dose
- Pharmaceutical form:
- pressurised inhalation suspension
- Quantity:
- 1
- Product type:
- Generic medicine
- Price:
- 90.61 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for salmeterol + fluticasone
Concentrations available for salmeterol + fluticasone
- 25mcg/125mcg
- 25mcg/125mcg/dose
- 25mcg/250mcg
- 25mcg/250mcg/dose
- 25mcg/50mcg
- 25mcg/50mcg/dose
- 50mcg/100mcg
- 50mcg/250mcg
- 50mcg/250mcg/dose
- 50mcg/500mcg
- 50mcg/500mcg/dose
- 50mg/100mg
- 50mg/250mg
- 50mg/500mg
Compensation lists for EVERIO 25mcg / 125mcg / dose Zentiva
B - Sublist B with 50% discount from the reference price
- Price
- 90.61 RON
- Copayment
- 31.17 RON
- Patient
- 59.44 RON